Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02157792 · ClinicalTrials.gov registry record · Phase 1
M6620 First in Human Study
A Phase 1 study, sponsored by EMD Serono Research & Development Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 200
- Enrollment target
NCT02157792 is a Phase 1 study that has completed, run by EMD Serono Research & Development Institute. The registered enrollment target is 200 participants.
The verdict
NCT02157792, a Phase 1 study, has completed, sponsored by EMD Serono Research & Development Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 200 participants
- Enrollment target
Study Summary
An Open-Label, First-in-Human Study of the Safety, Tolerability, and Pharmacokinetics (PK) of M6620 in Combination With Cytotoxic Chemotherapy in Participants With Advanced Solid Tumors
Interventions
- DRUG Carboplatin
- DRUG Cisplatin
- DRUG Etoposide
- DRUG Gemcitabine
- DRUG M6620
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2012-12-10 |
| Est. Completion | 2020-03-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02157792
The ClinicalTrials.gov registry entry for NCT02157792 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is EMD Serono Research & Development Institute, which has 81 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Carboplatin is the first listed.
NCT02157792 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02157792 about?
NCT02157792 is a clinical study titled "M6620 First in Human Study". An Open-Label, First-in-Human Study of the Safety, Tolerability, and Pharmacokinetics (PK) of M6620 in Combination With Cytotoxic Chemotherapy in Participants With Advanced Solid Tumors
What is the current status of trial NCT02157792?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 200 participants. The study started on 2012-12-10. Estimated completion is 2020-03-11.
What interventions are being tested in trial NCT02157792?
The interventions under investigation include: Carboplatin (DRUG), Cisplatin (DRUG), Etoposide (DRUG), Gemcitabine (DRUG), M6620 (DRUG).
Who is sponsoring clinical trial NCT02157792?
This trial is sponsored by EMD Serono Research & Development Institute, which has 81 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.